Vimseltinib (Romvilza) Gains Approval for Adult Treatment of Tenosynovial Giant Cell Tumours

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for vimseltinib (commercially known as Romvizma) to treat adult patients suffering from tenosynovial giant cell tumour (TGCT) when it affects their mobility or when surgical intervention is not a viable option.

Understanding Tenosynovial Giant Cell Tumour

Tenosynovial giant cell tumour is a rare, non-cancerous growth that typically develops around joints and tendons, predominantly affecting a single joint—most frequently the knee or ankle—in young to middle-aged adults. The condition can lead to a range of symptoms, including pain, swelling, stiffness, and reduced mobility, which can significantly impact daily activities.

Julian Beach, Executive Director for Healthcare Quality and Access at the MHRA, remarked on the significance of this development, stating:

“Our primary goals are to ensure patient safety and facilitate access to high-quality, safe, and effective medical products. The approval of vimseltinib introduces a new treatment avenue for patients with TGCT who experience symptoms but are not candidates for surgery. We will continue to closely monitor the safety of vimseltinib, as we do with all medical products.”

Mechanism of Action and Usage Instructions

The active component of Romvizma, vimseltinib, functions by inhibiting the proteins responsible for the growth of TGCTs, thereby slowing tumour progression. This medication is presented in capsule form and should be ingested whole with water, either with or without food, on a twice-weekly basis.

It is crucial to note that vimseltinib is subject to additional monitoring and is not recommended for use during pregnancy. Patients are advised to adhere strictly to the prescribed dosage and consult with their healthcare provider regarding any side effects experienced.

Potential Side Effects and Reporting

The most frequently reported side effects of vimseltinib, which may affect more than one in five patients, include fatigue, swelling around the eyes, ankles, and feet, itching, skin rashes, elevated blood pressure, increased liver enzyme levels, heightened cholesterol levels, increased creatinine levels, and decreased white blood cell counts (neutrophils).

Individuals who suspect they are experiencing side effects are encouraged to consult their doctor, pharmacist, or nurse and to report these incidents to the Yellow Card scheme for monitoring and safety purposes.

Further Information and Regulatory Context

The marketing authorisation for vimseltinib was officially granted on 14 August 2026 to Deciphera Pharmaceuticals. Additional information will be made available in the Summary of Product Characteristics and Patient Information leaflets, which will be accessible on the MHRA Products website within a week of the approval.

This product was submitted and approved through the International Recognition Procedure (IRP) Route B. The MHRA is tasked with regulating all medicines and medical devices in the UK, ensuring that they are effective and meet safety standards. Every decision made by the agency is founded on thorough, evidence-based assessments to confirm that the benefits outweigh any associated risks.

The MHRA operates as an executive agency under the Department of Health and Social Care. For any media inquiries, please reach out via email at newscentre@mhra.gov.uk or call 020 3080 7651.